Veralox Therapeutics
A clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway to address serious immune-mediated diseases.
The company’s lead candidate, VLX-1005, is in development for the treatment of patients with heparin-induced thrombocytopenia (HIT). VLX-1005 has orphan drug designation in the US and has been awarded Fast Track Designation by the US Food and Drug Administration. Second generation therapeutic products are under development for type I diabetes and other immune-mediated and inflammatory diseases.
Latest Veralox Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze